Education
About Us
Working with TipRanks
Follow Us
Jaguar Animal Health Inc. (JAGX)
NASDAQ:JAGX
JAGX Stock Chart & Stats
$1.28
-$0.07(-5.93%)
At close: 4:00 PM EST
$1.28
-$0.07(-5.93%)
Day’s Range― - ―
52-Week Range$0.56 - $25.75
Previous CloseN/A
Volume188.05K
Average Volume (3M)7.30M
Market Cap
$2.36M
Enterprise Value$29.75M
Total Cash (Recent Filing)$3.53M
Total Debt (Recent Filing)$31.90M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Apr 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.28
Shares Outstanding3,735,837
10 Day Avg. Volume370,730
30 Day Avg. Volume7,300,329
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.02
Price to Sales (P/S)0.64
P/FCF Ratio-0.25
Enterprise Value/Market Cap12.60
Enterprise Value/Revenue2.52
Enterprise Value/Gross Profit3.27
Enterprise Value/Ebitda-0.72
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross Margins (~77% TTM)Sustained ~77% gross margins indicate powerful unit economics for product sales. This margin profile can support investment in R&D and commercialization, absorb price or channel pressures, and materially improve profitability if fixed operating losses are reduced or revenue scales.
Progress In Crofelemer Rare‑disease ProgramMeaningful clinical and regulatory progress (FDA engagement, amended protocol and supportive PoC data) creates a credible pathway to orphan approvals. Orphan indications can command premium pricing with small patient populations, offering a durable route to high‑margin, specialty revenue if trials confirm benefit.
Non‑equity Licensing Deal With Upfront CashAn $18M upfront licensing payment plus milestones provides material non‑dilutive liquidity and shifts commercialization burden to a partner while Jaguar retains manufacturing and reacquisition optionality. This structure strengthens near‑term funding and preserves upside if clinical indications advance.
Bears Say
Heavy Operating Cash BurnPersistent ~-$26M TTM cash burn is a structural drain that forces reliance on external financing or partnerships. Over 2–6 months this constrains ability to fund trials/commercial expansion, increases dilution risk, and may force unfavorable financing terms or asset sales absent material revenue or deal milestones.
High Leverage And Thin Equity CushionDebt roughly 5.7x equity signals a fragile balance sheet and elevated refinancing or covenant risk. High leverage limits strategic flexibility, raises financing costs, and increases the probability of dilution or restrictive covenants that can hamper R&D or commercialization decisions over the medium term.
Falling Revenue And Very Large Net LossesA ~21% TTM revenue decline alongside deeply negative margins (~-342%) shows the business hasn't reached scalable commercial traction. Even with high gross margins, operating expenses far exceed sales; without durable revenue recovery or partner income, ongoing losses threaten long‑term self‑funding and increase dilution risk.
Jaguar Animal Health News
JAGX FAQ
What was Jaguar Animal Health Inc.’s price range in the past 12 months?
Jaguar Animal Health Inc. lowest stock price was $0.56 and its highest was $25.75 in the past 12 months.
What is Jaguar Animal Health Inc.’s market cap?
Jaguar Animal Health Inc.’s market cap is $2.36M.
When is Jaguar Animal Health Inc.’s upcoming earnings report date?
Jaguar Animal Health Inc.’s upcoming earnings report date is Apr 06, 2026 which is in 48 days.
How were Jaguar Animal Health Inc.’s earnings last quarter?
Jaguar Animal Health Inc. released its earnings results on Nov 17, 2025. The company reported -$6.28 earnings per share for the quarter, missing the consensus estimate of N/A by -$6.28.
Is Jaguar Animal Health Inc. overvalued?
According to Wall Street analysts Jaguar Animal Health Inc.’s price is currently Overvalued.
Does Jaguar Animal Health Inc. pay dividends?
Jaguar Animal Health Inc. does not currently pay dividends.
What is Jaguar Animal Health Inc.’s EPS estimate?
Jaguar Animal Health Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jaguar Animal Health Inc. have?
Jaguar Animal Health Inc. has 3,735,837 shares outstanding.
What happened to Jaguar Animal Health Inc.’s price movement after its last earnings report?
Jaguar Animal Health Inc. reported an EPS of -$6.28 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.404%.
Which hedge fund is a major shareholder of Jaguar Animal Health Inc.?
Currently, no hedge funds are holding shares in JAGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jaguar Animal Health Inc.
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
JAGX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a positive outlook with significant revenue growth and successful clinical trial results for crofelemer, along with strategic regulatory advancements and expansion plans in the animal health market. However, these positive developments were offset by increased operational losses and net loss attributable to shareholders.View all JAGX earnings summariesTechnical Analysis
Galmed Pharmaceuticals
―
Soligenix
―
Revelation Biosciences
―
Dermata Therapeutics
―
60 Degrees Pharmaceuticals, Inc.
―
Ownership Overview
4.75% Insiders
0.83% Mutual Funds
0.48% Other Institutional Investors
93.94% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---